Abstract
Chronic kidney diseases are characterized by a slow progressive loss of renal function leading to kidney failure. At end-stage renal disease, affected patients require renal replacement therapy, dialysis or kidney transplantation, with considerable consequences for mortality and quality of life of the patients. Since the prevalence of diabetes is increasing continuously in the general population, diabetic nephropathy is currently the number one cause of dialysis. The individual treatment of diabetic nephropathy and its resulting cardiovascular complications in the early and thus therapy-accessible phase of the disease is impeded by the lack of effective, non-invasive, valid routine diagnostic procedures for these patients. The currently used standard biomarkers serum creatinine/eGFR and urinary albumin are suitable to display DN in later stages, but they are of low significance in the detection of early stages. A new diagnostic method is based on the analysis of the proteome, the entirety of all proteins and peptides. Proteome analysis enabled the identification of 273 urinary biomarkers for the diagnosis of chronic renal disease. A classifier based on these biomarkers, CKD273, allows a significantly better identification of DN compared to the currently used biomarkers. The data specifically indicate an improvement in early diagnosis and prognosis. This allows an early and targeted therapy and therefore a significantly improved possibility to stop the progressive loss of renal function.
Translated title of the contribution | Proteomanalyse: Neue Wege zur verbesserten Behandlung der diabetischen Nephropathie |
---|---|
Original language | German |
Pages (from-to) | 213-221 |
Number of pages | 9 |
Journal | Diabetologie Und Stoffwechsel |
Volume | 12 |
Issue number | 3 |
DOIs | |
Publication status | Published - Jun 2017 |
Keywords
- diabetic nephropathy
- CKD273
- diagnosis
- prognosis
- CHRONIC KIDNEY-DISEASE
- RENAL-FUNCTION DECLINE
- URINARY PROTEOME
- BLOOD-PRESSURE
- CE-MS
- CARDIOVASCULAR OUTCOMES
- MICROALBUMINURIA
- PROGRESSION
- BIOMARKERS
- DIAGNOSIS